logo
Twitter
Discord
Email
logo
logo
Dianthus Therapeutics, Inc.NASDAQ - DNTH
Reports
Search reports
Name
Reporting Date
Filing Date
2024-09-30 10-Q2024-09-302024-11-07
2024-06-30 10-Q2024-06-302024-08-08
2024-03-31 10-Q2024-03-312024-05-09
2023-12-31 10-K2023-12-312024-03-21
2023-09-30 10-Q2023-09-302023-11-09
2023-06-30 10-Q2023-06-302023-08-03
2023-03-31 10-Q2023-03-312023-05-15
2022-12-31 10-K2022-12-312023-05-01
2022-12-31 10-K2022-12-312023-03-23
2022-09-30 10-Q2022-09-302022-11-03
2022-06-30 10-Q2022-06-302022-08-04
2022-03-31 10-Q2022-03-312022-05-16
2021-12-31 10-K2021-12-312022-03-08
2021-09-30 10-Q2021-09-302021-11-04
2021-06-30 10-Q2021-06-302021-08-05
2021-03-31 10-Q2021-03-312021-05-06
2020-12-31 10-K2020-12-312021-03-03
2020-09-30 10-Q2020-09-302020-11-05
2020-06-30 10-Q2020-06-302020-08-06
2020-03-31 10-Q2020-03-312020-05-07
1
2
20 / page
About
Name
Dianthus Therapeutics, Inc.
Overview
Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.
Show More
CEO
Mr. Marino Garcia M.B.A.
Industry
Biotechnology
Exchange
NASDAQ
Listing Date
2018-06-21
Address
7 Times Square, 43rd Floor, New York, NY, 10036, United States
Tel
929-999-4055
Website
https://dianthustx.com